| ||||||||||||||||||||||||
| ||||||||||||||||||||||||
| ||||||||||||||||||||||||
1 | AN ACT concerning health. | |||||||||||||||||||||||
2 | Be it enacted by the People of the State of Illinois, | |||||||||||||||||||||||
3 | represented in the General Assembly: | |||||||||||||||||||||||
4 | Section 1. Short title. This Act may be cited as the | |||||||||||||||||||||||
5 | Nonopioid Alternatives for Pain Act. | |||||||||||||||||||||||
6 | Section 3. Findings. The General Assembly finds that every | |||||||||||||||||||||||
7 | competent adult has the fundamental right of | |||||||||||||||||||||||
8 | self-determination regarding decisions pertaining to that | |||||||||||||||||||||||
9 | adult's own health, including the right to refuse an opioid | |||||||||||||||||||||||
10 | drug. | |||||||||||||||||||||||
11 | Section 5. Definitions. As used in this Act: | |||||||||||||||||||||||
12 | "Department" means the Department of Public Health. | |||||||||||||||||||||||
13 | "Emergency medical services personnel" has the meaning | |||||||||||||||||||||||
14 | given to that term in Section 3.5 of the Emergency Medical | |||||||||||||||||||||||
15 | Services (EMS) Systems Act. | |||||||||||||||||||||||
16 | "Health care practitioner" means a person licensed or | |||||||||||||||||||||||
17 | registered by the Department of Financial and Professional | |||||||||||||||||||||||
18 | Regulation under the following Acts: the Medical Practice Act | |||||||||||||||||||||||
19 | of 1987, the Nurse Practice Act, the Clinical Psychologist | |||||||||||||||||||||||
20 | Licensing Act, the Illinois Optometric Practice Act of 1987, | |||||||||||||||||||||||
21 | the Illinois Physical Therapy Act, the Pharmacy Practice Act, | |||||||||||||||||||||||
22 | the Physician Assistant Practice Act of 1987, the Clinical |
| |||||||
| |||||||
1 | Social Work and Social Work Practice Act, the Nursing Home | ||||||
2 | Administrators Licensing and Disciplinary Act, the Illinois | ||||||
3 | Occupational Therapy Practice Act, the Podiatric Medical | ||||||
4 | Practice Act of 1987, the Respiratory Care Practice Act, the | ||||||
5 | Professional Counselor and Clinical Professional Counselor | ||||||
6 | Licensing and Practice Act, the Illinois Speech-Language | ||||||
7 | Pathology and Audiology Practice Act, the Illinois Dental | ||||||
8 | Practice Act, the Illinois Dental Practice Act, or the | ||||||
9 | Behavior Analyst Licensing Act. | ||||||
10 | "Nonopioid directive form" means the form developed under | ||||||
11 | Section 20. | ||||||
12 | "Prescriber" has the meaning given to that term in | ||||||
13 | subsection (mm) of Section 102 of the Illinois Controlled | ||||||
14 | Substances Act. | ||||||
15 | Section 10. Nonopioid alternatives pamphlet. The | ||||||
16 | Department of Public Health shall develop and publish on its | ||||||
17 | website an educational pamphlet regarding the use of nonopioid | ||||||
18 | alternatives for the treatment of acute nonoperative, acute | ||||||
19 | perioperative, subacute, or chronic pain. The pamphlet shall, | ||||||
20 | at a minimum, conform with the most current CDC Clinical | ||||||
21 | Practice Guideline for Prescribing Opioids for Pain published | ||||||
22 | by the Centers for Disease Control and Prevention and shall | ||||||
23 | include: | ||||||
24 | (1) information on available nonopioid alternatives | ||||||
25 | for the treatment of pain, including available nonopioid |
| |||||||
| |||||||
1 | medicinal drugs or drug products and nonpharmacological | ||||||
2 | therapies; and | ||||||
3 | (2) the advantages and disadvantages of the use of | ||||||
4 | nonopioid alternatives. | ||||||
5 | Section 15. Prescription of opioids. | ||||||
6 | (a) A health care practitioner shall exercise professional | ||||||
7 | judgment in selecting appropriate treatment modalities for | ||||||
8 | acute nonoperative, acute perioperative, subacute, or chronic | ||||||
9 | pain in accordance with the most current CDC Clinical Practice | ||||||
10 | Guideline for Prescribing Opioids for Pain published by the | ||||||
11 | Centers for Disease Control and Prevention, including the use | ||||||
12 | of nonopioid alternatives whenever reasonable, clinically | ||||||
13 | appropriate, and evidence-based alternatives exist. | ||||||
14 | (b) The health care practitioner shall consider | ||||||
15 | prescribing nonopioids as the first line of pain control in | ||||||
16 | patients, unless the prescription is not clinically | ||||||
17 | appropriate, in accordance with subsection (a). | ||||||
18 | (c) Except when a patient is receiving care in a hospital | ||||||
19 | critical care unit or emergency department or a patient is | ||||||
20 | receiving hospice services under Hospice Program Licensing | ||||||
21 | Act, before providing care requiring the administration of | ||||||
22 | anesthesia involving the use of an opioid drug, or prescribing | ||||||
23 | or ordering an opioid drug for the treatment of pain, a health | ||||||
24 | care practitioner who prescribes or orders an opioid drug must | ||||||
25 | do all of the following: |
| |||||||
| |||||||
1 | (1) Inform the patient or the patient's representative | ||||||
2 | of available nonopioid alternatives for the treatment of | ||||||
3 | pain, which may include available nonopioid medicinal | ||||||
4 | drugs or drug products, interventional procedures or | ||||||
5 | treatments, acupuncture, chiropractic treatments, massage | ||||||
6 | therapy, physical therapy, occupational therapy, or any | ||||||
7 | other appropriate therapy as determined by the health care | ||||||
8 | practitioner. | ||||||
9 | (2) Discuss with the patient or the patient's | ||||||
10 | representative the advantages and disadvantages of the use | ||||||
11 | of nonopioid alternatives and whether the patient is at a | ||||||
12 | high risk of, or has a history of, controlled substance | ||||||
13 | abuse or misuse and the patient's personal preferences. | ||||||
14 | (3) Provide the patient or the patient's | ||||||
15 | representative, electronically or in printed form, with | ||||||
16 | the educational pamphlet described in Section 10. | ||||||
17 | (4) Document in the patient's record that nonopioid | ||||||
18 | alternatives were considered and discussed with the | ||||||
19 | patient or the patient's representative and, to the extent | ||||||
20 | that the health care practitioner prescribes or orders an | ||||||
21 | opioid for the treatment of pain, document the reasons for | ||||||
22 | such a prescription or order. | ||||||
23 | Section 20. Nonopioid directive form. The Department shall | ||||||
24 | develop a nonopioid directive form indicating to health care | ||||||
25 | practitioners and emergency medical services personnel that, |
| |||||||
| |||||||
1 | except as otherwise provided in Section 30 or in rules adopted | ||||||
2 | by the Department, a patient who has executed the form or who | ||||||
3 | has had a form executed on the patient's behalf must not be | ||||||
4 | administered an opioid or offered a prescription for an | ||||||
5 | opioid. The Department shall include on the nonopioid | ||||||
6 | directive form instructions on how the form may be revoked and | ||||||
7 | any other information that the Department considers relevant. | ||||||
8 | The Department shall make the form available to the public on | ||||||
9 | the Department's website. | ||||||
10 | Section 25. Nonopioid directive form; execution. A patient | ||||||
11 | may execute a nonopioid directive form on his or her own | ||||||
12 | behalf. A guardian or patient advocate of a patient may | ||||||
13 | execute a nonopioid directive form on behalf of the patient. | ||||||
14 | If a nonopioid directive form is executed by or on behalf of a | ||||||
15 | patient and is presented to a health care practitioner, the | ||||||
16 | health care practitioner shall obtain a copy of the form and | ||||||
17 | include the copy in the patient's medical record. A patient | ||||||
18 | may revoke a nonopioid directive form executed by himself or | ||||||
19 | herself at any time and in any manner by which he or she is | ||||||
20 | able to communicate his or her intent to revoke the form. A | ||||||
21 | patient advocate or guardian may revoke a nonopioid directive | ||||||
22 | form on behalf of a patient at any time by issuing the | ||||||
23 | revocation in writing and providing notice of the revocation | ||||||
24 | to the patient's health professional or his or her delegate. |
| |||||||
| |||||||
1 | Section 30. Administration of an opioid to a patient who | ||||||
2 | has executed a nonopioid directive form. A prescriber who | ||||||
3 | holds a controlled substances license or a health care | ||||||
4 | practitioner who is a practical nurse or registered | ||||||
5 | professional nurse and is acting on the order of the | ||||||
6 | prescriber may administer an opioid to a patient who has | ||||||
7 | executed a nonopioid directive form or who has had a nonopioid | ||||||
8 | directive form executed on his or her behalf if the patient is | ||||||
9 | being treated at a hospital or in a setting outside of a | ||||||
10 | hospital in the case of an emergency and, in the prescriber's | ||||||
11 | professional opinion, the administration of the opioid is | ||||||
12 | medically necessary to treat the patient. If an opioid is | ||||||
13 | administered under this Section, the prescriber shall ensure | ||||||
14 | that the patient is provided with information on substance use | ||||||
15 | disorder services. | ||||||
16 | Section 35. Limitation of liability. Except as otherwise | ||||||
17 | provided by law, the following are not subject to civil or | ||||||
18 | criminal liability or professional disciplinary action for | ||||||
19 | failing to administer, prescribe, or dispense an opioid, or | ||||||
20 | for the inadvertent administration of an opioid, to a patient | ||||||
21 | who has executed a nonopioid directive form or who has had a | ||||||
22 | nonopioid directive form executed on his or her behalf if the | ||||||
23 | failure to act or the act was done reasonably and in good | ||||||
24 | faith: | ||||||
25 | (1) A health care practitioner whose scope of practice |
| |||||||
| |||||||
1 | includes the prescribing, administering, or dispensing of | ||||||
2 | a controlled substance. | ||||||
3 | (2) A health facility or agency. | ||||||
4 | (3) An employee of a health care practitioner. | ||||||
5 | (4) An employee of a health facility or agency. | ||||||
6 | (5) Emergency medical services personnel. | ||||||
7 | Section 40. Rulemaking. The Department shall adopt rules | ||||||
8 | to implement this Act. The rules must allow a health care | ||||||
9 | practitioner or health facility or agency to incorporate a | ||||||
10 | nonopioid directive form into an existing patient form or into | ||||||
11 | other documentation used by the health care practitioner or | ||||||
12 | health facility or agency, and the rules must include, but not | ||||||
13 | be limited to, all of the following: | ||||||
14 | (1) Procedures to record a nonopioid directive form in | ||||||
15 | a medical record, including an electronic medical record. | ||||||
16 | (2) Procedures to revoke a nonopioid directive form. | ||||||
17 | (3) Procedures to ensure that the recording, | ||||||
18 | disclosure, or distribution of data relating to a | ||||||
19 | nonopioid directive form or the transmission of a | ||||||
20 | nonopioid directive form complies with State and federal | ||||||
21 | confidentiality and consent laws, rules, and regulations. | ||||||
22 | (4) Exemptions for administering or prescribing an | ||||||
23 | opioid to a patient who has executed a nonopioid directive | ||||||
24 | form or who has had a nonopioid directive form executed on | ||||||
25 | his or her behalf if the opioid is administered or |
| |||||||
| |||||||
1 | prescribed to treat the patient for a substance use | ||||||
2 | disorder. | ||||||
3 | (5) Exemptions for administering or prescribing an | ||||||
4 | opioid to a patient who has executed a nonopioid directive | ||||||
5 | form or who has had a nonopioid directive form executed on | ||||||
6 | his or her behalf if the patient is a hospice patient. | ||||||
7 | Section 100. The Illinois Insurance Code is amended by | ||||||
8 | adding Section 370c.3 as follows: | ||||||
9 | (215 ILCS 5/370c.3 new) | ||||||
10 | Sec. 370c.3. Coverage for nonopioid medications; pain | ||||||
11 | relief parity. | ||||||
12 | (a) In this Section, "health insurance issuer" has the | ||||||
13 | meaning set forth in Section 5 of the Illinois Health | ||||||
14 | Insurance Portability and Accountability Act. | ||||||
15 | (b) Notwithstanding any provision of law to the contrary, | ||||||
16 | when a licensed health care practitioner prescribes a | ||||||
17 | nonopioid medication for the treatment of acute pain, it shall | ||||||
18 | be unlawful for a health insurance issuer to deny coverage of | ||||||
19 | the nonopioid prescription drug in favor of an opioid | ||||||
20 | prescription drug or to require the patient to try an opioid | ||||||
21 | prescription drug prior to providing coverage of the nonopioid | ||||||
22 | prescription drug. | ||||||
23 | (c) In establishing and maintaining its drug formulary, a | ||||||
24 | health insurance issuer shall ensure that no nonopioid drug |
| |||||||
| |||||||
1 | approved by the United States Food and Drug Administration for | ||||||
2 | the treatment or management of pain shall be disadvantaged or | ||||||
3 | discouraged, with respect to coverage or cost sharing, | ||||||
4 | relative to any opioid or narcotic drug for the treatment or | ||||||
5 | management of pain on the health insurance issuer's drug | ||||||
6 | formulary, where impermissible disadvantaging or | ||||||
7 | discouragement includes, without limitation: imposing more | ||||||
8 | restrictive coverage criteria on any such nonopioid drug than | ||||||
9 | the least restrictive coverage criteria imposed on an opioid | ||||||
10 | or narcotic drug; establishing more restrictive or more | ||||||
11 | extensive utilization controls, including, but not limited to, | ||||||
12 | more restrictive or more extensive prior authorization or step | ||||||
13 | therapy requirements, for such nonopioid drug than the least | ||||||
14 | restrictive or extensive utilization controls applicable to | ||||||
15 | any such opioid or narcotic drug; or, if the health insurance | ||||||
16 | issuer maintains a drug formulary grouped into tiers for the | ||||||
17 | purposes of determining cost sharing, placing any such | ||||||
18 | nonopioid drug on a tier that requires a cost-sharing | ||||||
19 | responsibility that exceeds the lowest cost-sharing | ||||||
20 | responsibility required for any opioid or narcotic drug on the | ||||||
21 | drug formulary. | ||||||
22 | This subsection applies to a nonopioid drug immediately | ||||||
23 | upon its approval by the United States Food and Drug | ||||||
24 | Administration for the treatment or management of pain. | ||||||
25 | Section 105. The Illinois Public Aid Code is amended by |
| |||||||
| |||||||
1 | adding Section 5-55 as follows: | ||||||
2 | (305 ILCS 5/5-55 new) | ||||||
3 | Sec. 5-55. Coverage for nonopioid medications; pain relief | ||||||
4 | parity. | ||||||
5 | (a) Required coverage for nonopioid medications. | ||||||
6 | Notwithstanding any provision of law to the contrary, whenever | ||||||
7 | a licensed health care practitioner prescribes a nonopioid | ||||||
8 | medication for the treatment of acute pain, neither the | ||||||
9 | Department nor a managed care organization contracted with the | ||||||
10 | Department shall deny coverage of the nonopioid prescription | ||||||
11 | drug in favor of an opioid prescription drug or require a | ||||||
12 | patient to try an opioid prescription drug prior to providing | ||||||
13 | coverage of the nonopioid prescription drug. | ||||||
14 | (b) Pain relief parity. In establishing and maintaining | ||||||
15 | the Illinois Medicaid Preferred Drug List, the Department | ||||||
16 | shall ensure that no nonopioid drug approved by the U.S. Food | ||||||
17 | and Drug Administration for the treatment or management of | ||||||
18 | pain shall be disadvantaged or discouraged with respect to | ||||||
19 | coverage relative to any opioid or narcotic drug for the | ||||||
20 | treatment or management of pain on the Illinois Medicaid | ||||||
21 | Preferred Drug List, where impermissible disadvantaging or | ||||||
22 | discouragement includes, without limitation: designating any | ||||||
23 | such nonopioid drug as a nonpreferred drug if any opioid or | ||||||
24 | narcotic drug is designated as a preferred drug; or | ||||||
25 | establishing more restrictive or more extensive utilization |
| |||||||
| |||||||
1 | controls, including, but not limited to, more restrictive or | ||||||
2 | more extensive prior authorization or step therapy | ||||||
3 | requirements, for such nonopioid drug than the least | ||||||
4 | restrictive or extensive utilization controls applicable to | ||||||
5 | any such opioid or narcotic drug. This subsection applies to a | ||||||
6 | nonopioid drug immediately upon its approval by the U.S. Food | ||||||
7 | and Drug Administration for the treatment or management of | ||||||
8 | pain, regardless of whether such drug has been reviewed by the | ||||||
9 | Department for inclusion on the Illinois Medicaid Preferred | ||||||
10 | Drug List. This subsection also applies to drugs provided | ||||||
11 | under a contract between the Department and a managed care | ||||||
12 | organization. |